Status and phase
Conditions
Treatments
About
This prospective, global, multicenter, randomized, controlled study is designed to evaluate the safety and effectiveness of the Lutonix 035 AV Drug Coated Balloon PTA Catheter compared to a standard PTA Catheter in treating subjects presenting with clinical and hemodynamic abnormalities in native arteriovenous (AV) fistulae located in the upper extremity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Women who are pregnant, lactating, or planning on becoming pregnant during the study;
Hemodialysis access is located in the leg;
Subject has more than two lesions in the access circuit;
Subject has a secondary non-target lesion that cannot be successfully treated;
Target lesion is located central to the axillosubclavian junction;
The subject has a secondary lesion located in the central venous system (central to the axillosubclavian junction);
A thrombosed access;
Surgical revision of the access site planned;
Recent prior surgical interventions of the access site;
Other planned treatment during the index procedure;
Known contraindication (including allergic reaction) or sensitivity to iodinated contrast media, that cannot be adequately managed with pre-and post-procedure medication;
Known contraindication (including allergic reaction) or sensitivity to paclitaxel.
Subjects who are taking immunosuppressive therapy or are routinely taking
≥10mg of prednisone per day;
Subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be noncompliant with the protocol or confound the data interpretation;
Subject has a life expectancy <12 months;
Anticipated for a kidney transplant;
Anticipated conversion to peritoneal dialysis;
Subject has a stent located in the target or secondary non target lesion;
Subject has an infected AV access or systemic infection;
Currently participating in an investigational drug, biologic, or device study, or previous enrollment in this study.
Primary purpose
Allocation
Interventional model
Masking
285 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal